Considerations in Biosimilars Development – A US FDA Perspective

February 16, 2018

 

In this article, learn the key US specific concepts for clinical development programs as well as the regulatory aspects of biosimilar development for the US Market.

View the article here

Previous Article
Overcoming 3 Patient Safety Planning Pitfalls In Biosimilars
Overcoming 3 Patient Safety Planning Pitfalls In Biosimilars

Next Article
Aligning on Patient Outcomes – How Market Dynamics Can Facilitate RWD (Real World Data) Solutions in Research
Aligning on Patient Outcomes – How Market Dynamics Can Facilitate RWD (Real World Data) Solutions in Research

Read this presentation to find out more!

×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!